Abstract
The adenosine deaminase inhibitor deoxycoformycin was used in low doses to treat 19 patients with clinically aggressive T cell malignancy with a mature membrane phenotype. The patients comprised eight with prolymphocytic leukaemia, two with chronic lymphocytic leukaemia, four with adult T cell leukaemia-lymphoma, three with Sézary syndrome, and two with T cell lymphoma. Two thirds of the patients had been resistant or minimally responsive to combination chemotherapy. Complete remission was obtained in five patients (two with prolymphocytic leukaemia and one each with chronic lymphocytic leukaemia, adult T cell leukaemia-lymphoma, and Sézary syndrome) and partial remission in two others. Unmaintained complete remission lasting more than one year was seen in three patients. Responses were obtained only in patients with CD4+,CD8-membrane markers (seven out of 10), and no responses were recorded in any of the nine patients with a different phenotype. In this series remission appeared to correlate with the membrane phenotype of the neoplastic cell and not with the cytopathological diagnosis. Future studies should establish the biochemical basis for the greater sensitivity of CD4+ lymphoid cells to deoxycoformycin.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Grever M. R., Siaw M. F., Jacob W. F., Neidhart J. A., Miser J. S., Coleman M. S., Hutton J. J., Balcerzak S. P. The biochemical and clinical consequences of 2'-deoxycoformycin in refractory lymphoproliferative malignancy. Blood. 1981 Mar;57(3):406–417. [PubMed] [Google Scholar]
- Hoffbrand A. V., Ma D. D., Prentice H. G. Nucleotide metabolism and enzyme inhibitors in thymic acute lymphoblastic leukaemia. Haematol Blood Transfus. 1983;28:19–23. doi: 10.1007/978-3-642-68761-7_3. [DOI] [PubMed] [Google Scholar]
- Ma D. D., Massaia M., Sylwestrowicz T. A., Price G., Hoffbrand A. V. Comparison of purine degradative enzymes and terminal deoxynucleotidyl transferase in T cell leukaemias and in normal thymic and post-thymic T cells. Br J Haematol. 1983 Jul;54(3):451–457. doi: 10.1111/j.1365-2141.1983.tb02119.x. [DOI] [PubMed] [Google Scholar]
- Massaia M., Ma D. D., Sylwestrowicz T. A., Tidman N., Price G., Janossy G., Hoffbrand A. V. Enzymes of purine metabolism in human peripheral lymphocyte subpopulations. Clin Exp Immunol. 1982 Oct;50(1):148–154. [PMC free article] [PubMed] [Google Scholar]
- Seto S., Carrera C. J., Kubota M., Wasson D. B., Carson D. A. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J Clin Invest. 1985 Feb;75(2):377–383. doi: 10.1172/JCI111710. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Smyth J. F., Prentice H. G., Proctor S., Hoffbrand A. V. Deoxycoformycin in the treatment of leukemias and lymphomas. Ann N Y Acad Sci. 1985;451:123–128. doi: 10.1111/j.1749-6632.1985.tb27102.x. [DOI] [PubMed] [Google Scholar]
- Spiers A. S., Moore D., Cassileth P. A., Harrington D. P., Cummings F. J., Neiman R. S., Bennett J. M., O'Connell M. J. Remissions in hairy-cell leukemia with pentostatin (2'-deoxycoformycin). N Engl J Med. 1987 Apr 2;316(14):825–830. doi: 10.1056/NEJM198704023161401. [DOI] [PubMed] [Google Scholar]
- Spiers A. S., Ruckdeschel J. C., Horton J. Effectiveness of pentostatin (2'-deoxycoformycin) in refractory lymphoid neoplasms. Scand J Haematol. 1984 Feb;32(2):130–134. doi: 10.1111/j.1600-0609.1984.tb02167.x. [DOI] [PubMed] [Google Scholar]